The 24-Month Window Most Medical Device CEOs Don't Realize They're In

There are moments in the life of an industry when the rules quietly change and only the companies paying close attention notice in time to act. The mid-market medical device industry is in one of those moments right now. The next twenty-four months will determine which companies in this industry are still independently competitive in 2030 and which ones become acquisition targets, distressed assets, or quietly absorbed roll-up components.

Most CEOs in this industry do not feel this. Their quarterly results look fine. Procedure volumes are stable. The reps are hitting their numbers, mostly. The QBRs are unremarkable. The board meetings are not particularly tense.

The lack of urgency is the problem.

The competitive sorting is happening underneath the surface. By the time the sorting is visible in financial results, it is too late to act.

This piece is about the window I think mid-market device CEOs are in, the specific things that are about to compound across operational functions, and what to do across each major department before the window closes. It is an opinionated piece. It is meant to create urgency. The urgency is warranted.

What is actually happening

Three forces are converging in mid-market medical device right now, and they are converging at a pace that most operators are underestimating.

The technology curve has crossed a threshold

Until roughly 2023, operational AI deployment in mid-market device companies was theoretical. The language models were not capable enough to do the work that matters. The agent infrastructure was not mature enough to run unsupervised. The deployment patterns were not proven. CEOs who said "not yet, the technology isn't ready" were correct.

That is no longer correct. The current generation of models can credibly read unstructured complaint narratives and produce structured outputs. They can draft regulatory submissions from predicate libraries with high enough quality that human reviewers spend a fraction of the time they used to. They can manage surgeon adoption funnels with stage classification and next-best-action recommendations. They can sit inside a manufacturing operation and flag deviation patterns before they become CAPAs.

All of this works now. The technology has crossed the threshold. The companies who deploy in 2026 will get production results. The companies who wait until 2028 will be deploying the same systems but having lost twenty-four months of operational improvement compounding.

The competitive cohort is splitting

The mid-market device industry has roughly 1,370 companies in the US in the $10M-$1B revenue band. They have been competing on roughly equivalent operational sophistication for the past decade. Some are better at one function or another, but the variance has been narrow. Companies of similar size have looked similar from the outside.

This is changing. A small number of mid-market device companies are quietly deploying operational AI across functions and producing measurable improvements in rep productivity, regulatory cycle times, surgeon adoption rates, and quality operations efficiency. Most of these companies are not announcing the deployments. The improvements are showing up in their EBITDA, their growth rates, and their commercial momentum without being attributed publicly to AI.

The companies who are not deploying are looking at their flat metrics and concluding that the industry is just slow. They are not seeing the cohort that is pulling ahead because that cohort is not making noise about it. By the time the spread is visible in industry-wide benchmarks, it will be too established to close.

The procurement and exit math is shifting

PE-backed device platforms are increasingly being evaluated by sponsors on operational AI maturity as part of value-creation planning. The next round of acquisitions in this industry will increasingly use operational sophistication as a deal criterion. Strategic acquirers — Medtronic, Stryker, J&J MedTech — are starting to ask different questions in due diligence than they were asking five years ago. The data infrastructure, commercial operations sophistication, and regulatory operational maturity at a target company are increasingly material to deal valuations.

This matters for every mid-market device CEO whether or not they are planning an exit, because the same criteria that affect exit valuations affect the financing environment, the board conversation, and the strategic optionality the company has. Companies who are operationally modern have more options. Companies who are not are increasingly trapped in their current scale.

Why the window closes

The reason the window is bounded to roughly twenty-four months is that operational AI deployment compounds, and the compounding is not symmetrical between adopters and non-adopters.

Consider what happens at a company that deploys complaint triage AI in Q2 2026. By Q4 2026, the team has cleared the backlog and is operating at higher capacity. The QA director's time is freed up for root cause analysis and CAPA effectiveness verification. The company opens fewer CAPAs because issues are being identified earlier. The next year of regulatory inspections goes more smoothly. The team has more bandwidth for design control work on new product launches. Those products launch faster because the regulatory and quality teams are less constrained.

By 2028, that company has compounded two years of operational efficiency improvements across multiple functions. The rep productivity is higher. The regulatory cycle times are shorter. The surgeon adoption funnel is operationally managed. The complaint workflow is fast. The manufacturing operations are catching issues earlier. None of these are individually dramatic. Together, they are a different company.

Now consider the company that did not deploy. By 2028, they are roughly where they were in 2026, with all the same workflow inefficiencies and the same operational drag. They look at their faster-moving competitor and realize the gap. They engage a vendor. They start the same deployment journey their competitor started two years earlier. They will eventually get there. But they will have lost twenty-four months of compounding, and they will be deploying into a competitive environment where their competitors have already established structural advantages.

Twenty-four months of compounded operational improvement is not a gap that can be closed by a year of intense effort later.

This is why the window is finite. The technology is available now. The early adopters are deploying now. The compounding is starting now. The companies who wait will not be running the same race. They will be entering the race after the leaders have already lapped them.

What to do in the next twenty-four months, by department

If I were a mid-market device CEO with a twenty-four-month window, here is the specific work I would commission across each major function. The sequencing matters. The investments compound. The companies who follow this pattern will look fundamentally different by 2028.

Quality operations: build the modern complaint and CAPA function

Months 1-6: deploy AI-augmented complaint triage. The deployment I have written about extensively elsewhere. The investment is modest and the operational impact is fast. By month six, complaint cycle times are dramatically shorter and your QA team's time is reallocated toward higher-value work.

Months 7-12: extend into CAPA management. The same AI capability that triages complaints can identify patterns across complaints that should become CAPAs. The system surfaces patterns earlier, which means CAPAs are opened with smaller scope and remediated faster.

Months 13-18: integrate post-market surveillance and complaint trending into a unified system. The QA function moves from reactive complaint handling to proactive pattern detection. The FDA inspection profile improves measurably.

Months 19-24: by the end of the window, your quality operations function is operating at a different level than competitors who did not invest. Your QA director's job has fundamentally changed. The team has bandwidth for design control and process improvement work that competitors cannot match.

Regulatory operations: compress your submission cycle

Months 1-6: deploy the 510(k) drafting co-pilot. Compress your average submission preparation time by fifty percent within the first three submissions.

Months 7-12: extend AI capability into change control documentation, design history file maintenance, and regulatory correspondence drafting. The RA team's mechanical workload drops by half. The team's bandwidth for strategic regulatory work expands.

Months 13-18: build out the predicate intelligence layer. The system tracks competitor submissions, monitors FDA clearance patterns in your category, and surfaces strategic insights. Your regulatory strategy is informed by structured market intelligence rather than ad-hoc reading.

Months 19-24: by the end of the window, your regulatory function is filing more submissions per year than competitors, with shorter cycle times, and contributing strategic intelligence to product planning that competitors are doing manually.

Commercial operations: build the surgeon adoption operating system

Months 1-6: deploy the surgeon adoption funnel management system. Stage classification, stalled surgeon detection, next-best-action recommendations to reps. The marketing team finally has visibility into education program ROI. The sales team finally has consistent stage management.

Months 7-12: extend into rep onboarding with AI-augmented training, surgeon prep dossier generation, and certification gates. New reps ramp twenty to thirty percent faster. Time-to-first-case compresses meaningfully.

Months 13-18: build the unified cross-channel surgeon record across W2 reps, 1099 reps, distributors, and KOL relationships. The commercial leadership team has line-of-sight into channel productivity that competitors are still managing through email and QBRs.

Months 19-24: by the end of the window, your commercial operations look fundamentally different. Time-to-routine-adopter for surgeons in your funnel is compressed. New rep ramp times are shorter. Distributor performance management is data-driven. The commercial efficiency compounds across multiple metrics.

Manufacturing operations: build the operational intelligence layer

Months 1-6: deploy deviation pattern detection on the manufacturing floor. Surface emerging quality patterns before they become CAPAs.

Months 7-12: extend into supplier quality monitoring. Track supplier performance with structured signal detection. Identify supplier risk earlier than competitors who are reviewing nonconformance reports quarterly.

Months 13-18: deploy yield optimization and process variability monitoring. Manufacturing leadership has continuous visibility into process performance rather than waiting for monthly reports.

Months 19-24: the manufacturing operation is operating at lower variability, with higher yields, fewer disruptions, and better supplier management than competitors. The cost structure improvements compound.

Distributor and channel operations: build the federation visibility layer

Months 1-6: deploy the distributor data standardization layer. Normalize inconsistent reports from distributor partners into unified visibility. The VP of Sales finally has real-time channel productivity data.

Months 7-12: extend into distributor performance management with structured benchmarking and underperformance detection. The QBR conversation with distributor partners becomes data-driven rather than feel-driven.

Months 13-18: build the cross-channel surgeon view that connects W2 rep activity, distributor activity, and KOL relationships into one operational picture. The federation operates as a managed network rather than a collection of independent agents.

Months 19-24: your hybrid commercial model is operating with visibility and support that competitors cannot match. Distributor productivity is measurably higher because they are supported with tools rather than left to operate independently.

Document control and quality system: complete the QMSR modernization

Months 1-6: deploy the QMS mapping and modernization project. Bring your quality system into full alignment with QMSR and ISO 13485 risk-based thinking. Document the current state. Identify gaps.

Months 7-12: execute the SOP rewriting and training program. Use AI augmentation to draft updated procedures. Roll out training. Verify adoption.

Months 13-18: build the continuous quality system monitoring layer. Your QMS is no longer a document graveyard. It is a living operational system that adapts to changes in product portfolio, regulation, and process.

Months 19-24: by the end of the window, your QMS is a competitive asset. Inspections go more smoothly. Audits find fewer issues. New products move through the system faster. The quality function is operationally sophisticated in a way that competitors are not.

Field operations and post-market

Months 1-6: deploy field service ticket triage and resolution intelligence if your product portfolio includes capital equipment or any field service component.

Months 7-12: integrate field service data with complaint handling and post-market surveillance. The full picture of product performance in the field becomes available in real time.

Months 13-18: build the predictive maintenance and proactive support capability that turns field operations from a reactive cost center into a strategic differentiator.

Months 19-24: field operations is operating at a higher level than competitors. Customer experience improves measurably. Service revenue, where applicable, becomes a meaningful contributor rather than a break-even function.

The total picture by 2028

A company that deploys this sequence over the next twenty-four months will look like this in mid-2028:

Their quality operations clear complaints within five days on average. Their open complaints over thirty days are under three percent of the queue. Their CAPA cycle times are forty percent shorter. Their FDA inspection findings are minimal.

Their regulatory function is filing five to seven submissions per year instead of three to four. Their submission preparation time is half what it used to be. They are launching one to two additional products per year compared to where they would be.

Their commercial operations are managing surgeons through a unified funnel across all channels. New reps are reaching quota in six months instead of nine. Stalled surgeon detection has improved conversion rates by ten to fifteen percent.

Their manufacturing operation is running at lower variability with higher yields. Supplier quality is more visible. Deviation patterns are caught earlier. The cost structure is meaningfully better.

Their distributor channel is operating with visibility and support that competitors cannot match. Distributor productivity is higher. Channel transitions are managed proactively.

Their QMS is a living operational system. Their post-market surveillance is integrated. Their field operations contribute strategically.

Total operational improvement: a meaningfully different company than they were in 2026. EBITDA margins are several hundred basis points higher. Growth rates are higher. Strategic optionality is greater. The company is positioned differently in any acquisition conversation.

Now consider the company that did not deploy. Same products. Same reps. Same QBR rituals. Same complaint backlogs. Same regulatory cycle times. Same hand-managed distributor relationships. Same QMS that needs another year of mapping work. The company is roughly where it was in 2026, while the competitor that did invest is fundamentally different.

The gap is twenty-four months of compounded operational improvement. It is not bridgeable by an aggressive eighteen-month catch-up plan starting in 2028. The companies who win this window will win it permanently.

The objection and the response

Every CEO reading this is having one of three reactions. Some are nodding because they have already started this work. Some are skeptical because they have been pitched too many times. Most are uncertain because the urgency feels artificial.

The objection is usually some version of: "we're doing fine, our metrics are healthy, why now?"

The response is that the metrics are healthy because the competitive cohort has been moving at roughly the same pace. The cohort is now splitting. By the time the metrics show the split, the split is too established to address. The question is not whether your current metrics are acceptable. The question is whether your current metrics in 2028 will be competitive against companies who deployed operational AI in 2026.

The CEOs who are already moving on this are not loud about it. They are not announcing AI initiatives or hiring chief AI officers or running press cycles. They are quietly deploying systems in their basement functions, building operational muscle, and compounding improvements. They will be visible in 2028, not 2026.

If you wait until you can see the pattern in industry benchmarks, you will be too late.

The reframe

Mid-market medical device CEOs are in a window. The window is real, the timing is finite, and the consequences of missing it compound.

The work to do in the next twenty-four months is specific and tractable. It does not require a moonshot strategy or a massive transformation initiative. It requires sequenced operational deployments across the major functions of the company, starting in the unglamorous basement and expanding into the customer-facing functions as the company builds operational muscle.

The companies that follow this pattern will be measurably different by 2028. The companies that do not follow this pattern will be roughly where they are today, while competitors who did the work pull ahead in ways that are increasingly hard to close.

The most expensive thing you can do in 2026 is not picking the wrong AI vendor. It is choosing not to start. The second most expensive thing is starting on the flashy customer-facing deployment and burning your organizational credibility on a project that fails.

Start in the basement. Build the operational muscle. Compound for twenty-four months. By 2028, you will be a different company than you are today. The competitors who did not do this work will be looking up at the gap, wondering when it opened.

The window is open now. It will not be open forever.